MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Revenue
$120,877K
Net Income
-$16,790K
Net Profit Margin
-13.89%
EPS
-$0.07
Unit: Thousand (K) dollars
Revenue Breakdown
    • Product IBSRELA
    • Product XPHOZAH
    • Revenue From Contract With Custo...
    • Others
Revenue Breakdown
    • Product
    • Product Supply Revenue
    • Non Cash Royalty Related To Sale...
    • License
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
120,877
94,473
125,215
110,329
Cost of sales
5,759
4,811
10,849
3,982
Research and development
26,103
20,188
22,856
18,067
Selling, general and administrative
101,440
102,267
86,411
83,612
Total costs and operating expenses
133,302
127,266
148,804
101,679
Gain from operations
-12,425
-32,793
5,099
4,668
Interest expense
4,957
5,599
5,759
5,796
Non-cash interest expense related to the sale of future royalties
1,267
1,317
1,818
2,188
Other income, net
2,038
2,112
2,078
2,449
Loss before provision for income taxes
-16,611
-37,597
-400
-867
Provision for income taxes
110
8
7
102
Net loss
-16,721
-37,605
-407
-969
Unrealized losses on available-for-sale securities
-69
-322
74
162
Comprehensive loss
-16,790
-37,927
-333
-807
Basic EPS
-0.07
-0.15
-0.001
0
Diluted EPS
-0.07
-0.15
-0.001
0
Basic Average Shares
248,067,253
245,855,082
243,673,878
241,908,407
Diluted Average Shares
248,067,253
245,855,082
243,673,878
241,908,407
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Comprehensive loss-$16,790K (12.26%↑ Y/Y)Revenue From ContractWith Customer...$1,976K License AgreementDevelopment...$95K Knight TherapeuticsInc-License Agreement...$1K Net loss-$16,721K (12.36%↑ Y/Y)Unrealized losses onavailable-for-sale securities-$69K (-23.21%↓ Y/Y)Product IBSRELA$86,243K Product XPHOZAH$31,886K Product Supply Revenue$1,976K (-68.05%↓ Y/Y)Kyowa KirinCo.Ltd-License Agreement...$676K License$96K (380.00%↑ Y/Y)Loss beforeprovision for income taxes-$16,611K (12.93%↑ Y/Y)Provision for income taxes$110K (10900.00%↑ Y/Y)Other income, net$2,038K (7.72%↑ Y/Y)Product$118,129K (31.14%↑ Y/Y)Product And ServiceOther$2,748K (-63.77%↓ Y/Y)Gain from operations-$12,425K (13.69%↑ Y/Y)Interest expense$4,957K (13.80%↑ Y/Y)Total revenues$120,877K (23.77%↑ Y/Y)Non-cash interestexpense related to the...$1,267K (-42.90%↓ Y/Y)Total costs andoperating expenses$133,302K (33.76%↑ Y/Y)Selling, general andadministrative$101,440K (20.78%↑ Y/Y)Research and development$26,103K (66.62%↑ Y/Y)Cost of sales$5,759K (-53.57%↓ Y/Y)

ARDELYX, INC. (ARDX)

ARDELYX, INC. (ARDX)